Evidence map›Paper›PMID 42062708›Full record

ArticleGeroScience2026

Autophagy revealed as a targetable vulnerability in senescent cells by cell painting phenotypic profiling: a mechanistic study of MCOPPB and related compounds.

Matthew Lacey, Lucie Beresova, Alzbeta Srovnalova, Pavlo Polishchuk, Michal Sala, Zdenek Skrott, Marian Hajduch, Petr Dzubak, Jiri Bartek, Anna Siskova and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matthew LaceyInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Lucie BeresovaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Alzbeta SrovnalovaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Pavlo PolishchukInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Michal SalaInstitute of Organic Chemistry and Biochemistry of the, Czech Academy of Science, CAS, Prague, Czech Republic.
Zdenek SkrottInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Marian HajduchInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Petr DzubakInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Jiri BartekDanish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
Anna SiskovaInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Martin LoffelmannInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
Radim NenckaInstitute of Organic Chemistry and Biochemistry of the, Czech Academy of Science, CAS, Prague, Czech Republic.
Martin MistrikInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic. martin.mistrik@upol.cz.ORCID http://orcid.org/0000-0002-2321-0348

Funding

Czech Academy of Sciences RVO: 61388963Kræftens Bekæmpelse R322-A17482Ministerstvo Školství, Mládeže a Tělovýchovy CZ.02.01.01/00/22_008/0004607Ministerstvo Školství, Mládeže a Tělovýchovy LM2023050Ministerstvo Školství, Mládeže a Tělovýchovy LM2023052Ministerstvo Školství, Mládeže a Tělovýchovy LM2023053Ministerstvo Školství, Mládeže a Tělovýchovy SALVAGE CZ.02.01.01/00/22_008/0004644NextGenerationEU LX22NPO5102Univerzita Palackého v Olomouci IGA-UP-2021Univerzita Palackého v Olomouci JG_2023_33
6 · The paper itself

Abstract

Senescent cells accumulate with age and contribute to tissue dysfunction and chronic inflammation. Senolytic agents that selectively eliminate senescent cells hold therapeutic promise; however, few mechanistic classes have been established. Using Cell Painting-based morphological profiling, we identified a distinct cluster of senolytic compounds comprised of both known and novel autophagy inhibitors, including AZ191, bafilomycin A1, chloroquine, daurisoline, dauricine, MCOPPB, and its derivative MS1108. These compounds selectively eliminated senescent cells by disrupting autophagic flux. Our findings reveal senescent cell dependence on autophagy as an essential survival mechanism, define the existence of a mechanistically distinct class of senolytics acting through autophagy inhibition, and demonstrate the predictive value of Cell Painting in aging-related drug discovery. Our results provide new insights into senescent cell vulnerability and expand the therapeutic landscape for aging-related pathologies by highlighting autophagy as a targetable dependency.

Indexed as

AutophagyCell PaintingProteotoxic stressSASPSenescenceSenolytics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.